Along with our updated website we are also launching the first edition of our company updates. We intend to publish these quarterly to provide regular updates on activities at mAbsolve. As the first such update in two years since our founding this will look back a bit further. The last two years has seen the … Read more

When the company was founded in December 2019 we were a startup with an interesting technology in the early stages of development. Still in stealth mode at the time, a website wasn’t our top priority and so we quickly put something together as a temporary measure. As a company founded and managed by scientists it … Read more

mAbsolve’s international patent application on a novel Fc silencing technology has today been published under application number WO/2021/234402.

Starting today Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer, having been a Founder and non-executive Director since the company’s induction in December 2020. Ian brings a wealth of experience in the development and commercialisation of antibody technologies having previously been Chief Scientific Officer at Absolute Antibody, taking that organisation from start-up through to … Read more

mAbsolve has today filed an international patent application PCT/GB2021/051233 on its novel Fc silencing technology.

After a period of research and development mAbsolve today announces the formal launch of its Fc silencing technology named STR. Access to the technology platform will be made available through research and commercial licences. mAbsolve scientists and partners have performed extensive in vitro and in vivo analysis of the Fc mutations collecting demonstrating that STR … Read more

mAbsolve has today filed a patent on its novel Fc silencing technology, GB2007613.9.